Amgen acquired worldwide rights to psoriasis drug Otezla (apremilast) For $13.4 Billion
On Aug. 26, 2019, Amgen acquired worldwide rights to Otezlaﾮ (apremilast), the only oral, non-biologic treatment for psoriasis…
psoriasis
On Aug. 26, 2019, Amgen acquired worldwide rights to Otezlaﾮ (apremilast), the only oral, non-biologic treatment for psoriasis…